Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 15, 2003; DOI: 10.1124/jpet.103.051797
0022-3565/03/3063-954-964$20.00
JPET 306:954-964, 2003
NEUROPHARMACOLOGY
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
M. J. Millan,
A. Gobert,
F. Lejeune,
A. Dekeyne,
A. Newman-Tancredi,
V. Pasteau,
J.-M. Rivet, and
D. Cussac
Department of Psychopharmacology, Institut de Recherches Servier,
Croissy/Seine, France
Agomelatine (S20098) displayed pKi values of 6.4 and
6.2 at native (porcine) and cloned, human (h)5-hydroxytryptamine
(5-HT)2C receptors, respectively. It also interacted with
h5-HT2B receptors (6.6), whereas it showed low affinity at native
(rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A
(<5.0/5.2) receptors, and negligible (<5.0) affinity for other 5-HT
receptors. In antibody capture/scintillation proximity assays, agomelatine
concentration dependently and competitively abolished h5-HT2C
receptor-mediated activation of Gq/11 and Gi3
(pA2 values of 6.0 and 6.1). As measured by
[3H]phosphatidylinositol depletion, agomelatine abolished
activation of phospholipase C by h5-HT2C (pKB
value of 6.1) and h5-HT2B (pKB value of 6.6)
receptors. In vivo, it dose dependently blocked induction of penile erections
by the 5-HT2C agonists
(S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine (Ro60,0175)
and
1-methyl-2-(5,8,8-trimethyl-8H-3-aza-cyclopenta[a]inden-3-yl)
ethylamine (Ro60,0332). Furthermore, agomelatine dose dependently enhanced
dialysis levels of dopamine in frontal cortex of freely moving rats, whereas
they were unaffected in nucleus accumbens and striatum. Although the
electrical activity of ventrotegmental dopaminergic neurons was unaffected
agomelatine, it abolished their inhibition by Ro60,0175. Extracellular levels
of noradrenaline in frontal cortex were also dose dependently enhanced by
agomelatine in parallel with an acceleration in the firing rate of adrenergic
cell bodies in the locus coeruleus. These increases in noradrenaline and
dopamine levels were unaffected by the selective melatonin antagonist
N-[2-(5-ethyl-benzo[b]thien-3-yl)ethyl] acetamide (S22153)
and likely flect blockade of 5-HT2C receptors inhibitory to
frontocortical dopaminergic and adrenergic pathways. Correspondingly,
distinction to agomelatine, melatonin showed negligible activity
5-HT2C receptors and failed to modify the activity of adrenergic
and dopaminergic pathways. In conclusion, in contrast to melatonin,
agomelatine behaves as an antagonist at 5-HT2B and
5-HT2C receptors: blockade of the latter reinforces frontocortical
adrenergic and dopaminergic transmission.
Received March 18, 2003;
accepted April 30, 2003.
Address correspondence to: Dr. Mark J. Millan, Institut de Recherches
Servier, 125 chemin de Ronde 78290 Croissy/Seine, France. E-mail:
mark.millan{at}fr.netgrs.com
This article has been cited by other articles:

|
 |

|
 |
 
C. R Dolder, M. Nelson, and M. Snider
Agomelatine Treatment of Major Depressive Disorder
Ann. Pharmacother.,
December 1, 2008;
42(12):
1822 - 1831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y Le Strat and P Gorwood
Agomelatine, an innovative pharmacological response to unmet needs
J Psychopharmacol,
September 1, 2008;
22(7_suppl):
4 - 8.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Goodwin
Innovation translates into antidepressant effectiveness
J Psychopharmacol,
September 1, 2008;
22(7_suppl):
9 - 12.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Lam
Addressing circadian rhythm disturbances in depressed patients
J Psychopharmacol,
September 1, 2008;
22(7_suppl):
13 - 18.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. McClung
Role for the Clock Gene in Bipolar Disorder
Cold Spring Harb Symp Quant Biol,
January 1, 2007;
72(0):
637 - 644.
[Abstract]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.